What Causes PARP Inhibitor Resistance in BRCA Cancers?

When you take a PARP inhibitor as a maintenance therapy for a BRCA-related cancer, the drug works by blocking a key DNA repair process. Since your cancer cells already have a broken DNA repair system due to the BRCA mutation, losing this second repair process causes the cancer cells to die. However, over time, cancer cells can adapt and survive the medication. When this happens, it is known as acquired resistance. The most common way this happens is through new, random genetic mutations that occur and “fix” the broken BRCA gene, restoring the cell’s ability to repair its own DNA ^[1][2].

How Does Cancer Outsmart PARP Inhibitors?

To understand how resistance happens, it helps to look at the specific “escape routes” cancer cells develop.

Reversion Mutations (The “Fix-It” Strategy)

The most common cause of PARP inhibitor resistance is a phenomenon called reversion mutations ^[1]. When you have a BRCA mutation, your cancer cells lack a functional system called homologous recombination (HR)—a highly accurate way cells fix broken DNA. PARP inhibitors exploit this weakness ^[1][3].

However, under the continuous pressure of the drug, the tumor can acquire new genetic mutations that reverse the effects of the original BRCA mutation ^[2]. These new mutations do not always perfectly “undo” the original genetic error, but they alter the gene’s sequence just enough to produce a functional or partially functional repair protein. This essentially restores the cancer cell’s HR repair system, allowing it to fix the DNA damage caused by the PARP inhibitor and continue growing ^[3].

Other Escape Routes

While reversion mutations are the most common culprit, cancer cells can acquire resistance through a few other mechanisms:

• Pumping the drug out: Cancer cells can increase the number of molecular “pumps” on their surface, allowing them to flush the PARP inhibitor out of the cell before it can do its job (a process called drug efflux) ^[4][5].
• Protecting the DNA replication process: Even without a functional BRCA protein, tumors can undergo changes that find alternative ways to stabilize their DNA while they are dividing, making them less vulnerable to the drug ^[6][4].
• Losing the PARP target: PARP inhibitors work by physically trapping the PARP protein onto the cancer cell’s DNA. If the cancer cell stops producing the PARP protein, or if the protein mutates to change its shape, the drug loses its target and can no longer trap it ^[7][4].

How Do Doctors Monitor for Resistance?

Resistance often starts at a genetic, microscopic level before a tumor physically grows large enough to be seen on a CT or MRI scan, and typically before you would feel any new or returning physical symptoms ^[8]. Because of this, routine monitoring is vital.

Doctors are increasingly using liquid biopsies to monitor for these microscopic changes ^[8][9]. A liquid biopsy is a simple blood test that looks for circulating tumor DNA (ctDNA)—tiny fragments of genetic material that cancer cells shed into your bloodstream. By analyzing this ctDNA, doctors can often detect if a reversion mutation has developed in real-time ^[8][10]. This non-invasive tool helps your oncology team understand exactly how your cancer is evolving and can guide them in deciding if it is time to switch to a different treatment strategy ^[9][11].

What Happens Next?

Learning that your cancer has stopped responding to a maintenance therapy can be deeply frustrating and anxiety-inducing. However, PARP resistance does not mean you are out of options. Identifying the specific mechanism of resistance—like finding a reversion mutation via a liquid biopsy—helps your care team select the most effective next step ^[11].

Currently, researchers are heavily focused on overcoming PARP resistance. Clinical trials are testing new combinations of drugs to block the new escape routes the cancer has developed. For example, researchers are pairing PARP inhibitors with other targeted therapies (like ATR inhibitors or Polθ inhibitors), which are drugs that target different “backup” DNA repair systems ^[12][13]. Based on your tumor’s updated genetic profile, your doctor may also recommend transitioning to a different type of chemotherapy or an entirely new class of targeted medication ^[9][11].